Mandate

Vinge advises PPR S.A in connection with the sale of Ellos and Jotex

February 25, 2013

Vinge has advised PPR S.A in connection with the sale of Ellos and Jotex to Nordic Capital Fund VII for an enterprise value of €275 million. Ellos is the leading home shopping player in Scandinavia for apparel and Jotex has established itself as a key player in the Scandinavian home textile and decoration market.

PPR S.A is one of the world’s leading apparel and accessories groups that operates in the two fastest growing market segments: Luxury and Sport & Lifestyle. The PPR Group has built a balanced collection of complementary consumer brands, including for example Gucci, Bottega Veneta, Saint Laurent, Alexander McQueen, Stella McCartney, Sergio Rossi, Girard-Perregaux, Puma and Tretorn. Present in more than 120 countries, the PPR Group generated revenues of €9.7 billion in 2012 and had over 33,000 employees at year end. The PPR share is listed on Euronext Paris.

The transaction is subject to approval of relevant competition authorities.

Vinge’s team consisted of responsible partner Johan Winnerblad together with, among others, Christina Kokko (partner) and associates Joacim Rydergård, Alex Miler, Eric Ödling, Karl Hahtovirta and project assistant Annika Johnson.

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025